Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.45 |
| ▸ | TRHR | P34981 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489849 | 1.00 | ACE (0.51) | ACECAPN1OPRM1LTA4HOPRD1 | |
| SCHEMBL9509798 | 0.94 | ACE (0.48) | ACECAPN1OPRM1LTA4HOPRD1 | |
| SCHEMBL9509803 | 0.94 | ACE (0.48) | ACECAPN1OPRM1LTA4HOPRD1 | |
| SCHEMBL9551637 | 0.89 | TSHR (0.55) | ACEOPRM1 | |
| SCHEMBL9508374 | 0.89 | BCHE (0.50) | ACEOPRM1OPRD1 | |
| SCHEMBL9551636 | 0.89 | TSHR (0.55) | ACEOPRM1 | |
| SCHEMBL9508378 | 0.89 | BCHE (0.50) | ACEOPRM1OPRD1 | |
| SCHEMBL9509721 | 0.89 | STAT3 (0.54) | — | |
| SCHEMBL9509727 | 0.89 | STAT3 (0.54) | — | |
| SCHEMBL10586296 | 0.87 | OPRM1 (0.41) | ACECAPN1OPRM1OPRD1TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163922-B2 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system | NEUROTELL AG (CH) | 2007-01-16 | — | — | US | claimed |
| EP-1390055-B1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2005-11-23 | — | — | EP | claimed |
| US-20050192228-A1 | Tripeptide derivatives for the treatment of neurodegenerative diseases | NEUROTELL AG (CH) | 2005-09-01 | — | — | US | claimed |
| US-20050101539-A1 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system | NEUROTELL AG (CH) | 2005-05-12 | — | — | US | claimed |
| EP-1390055-A2 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | Neurotell AG (CH) | 2004-02-25 | — | — | EP | claimed |
| EP-1358204-A1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Neurotell AG (CH) | 2003-11-05 | — | — | EP | claimed |
| WO-2002062830-A1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | claimed |
| WO-2002062372-A2 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | claimed |
| EP-0316218-B1 | L-PROLINE DERIVATIVES, THEIR PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | EKITA Investments N.V. (NA) | 1993-09-15 | — | — | EP | claimed |
| US-5212158-A | Nootropic agents | INORGAN SA RECHERCHE & DEVELOPPEMENT PHARMACEUTIQUES, CAS (CH) | 1993-05-18 | — | — | US | claimed |
| JP-1157998-A | — | — | None | — | — | JP | disclosed |
| US-7163922-B2 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system | NEUROTELL AG (CH) | 2007-01-16 | — | — | US | disclosed |
| EP-1359934-B1 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| EP-1390055-B1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| US-20050192228-A1 | Tripeptide derivatives for the treatment of neurodegenerative diseases | NEUROTELL AG (CH) | 2005-09-01 | — | — | US | disclosed |
| WO-2002062372-A2 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062830-A1 | TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | disclosed |
| EP-0316218-B1 | L-PROLINE DERIVATIVES, THEIR PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | EKITA Investments N.V. (NA) | 1993-09-15 | — | — | EP | disclosed |
| US-5212158-A | Nootropic agents | INORGAN SA RECHERCHE & DEVELOPPEMENT PHARMACEUTIQUES, CAS (CH) | 1993-05-18 | — | — | US | disclosed |
| JP-H01157998-A | L-PROLINE DERIVATIVE, ITS PRODUCTION AND MEDICINE COMPOSITION CONTAINING THE SAME | INORGAN SA RECH & DEV PHARMACEUT | 1989-06-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101539-A1 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system | ARGLU1, VIP, ASNS | ACE 1032/4885CAPN1 2647/4885OPRM1 740/4885 |
| US-20050192228-A1 | Tripeptide derivatives for the treatment of neurodegenerative diseases | ARGLU1, ASNS, KYNU | ACE 1590/4885CAPN1 1657/4885OPRM1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.